Table 1. Characteristics of the three Epstein-Barr virus antibody assays.
| Architect | Liaison | Platelia | |||||||
|---|---|---|---|---|---|---|---|---|---|
| VCA IgM | VCA IgG | EBNA IgG | VCA IgM | VCA IgG | EBNA IgG | VCA IgM | VCA IgG | EBNA IgG | |
| Method | CMIA | CLIA | ELISA | ||||||
| Sample | Serum or plasma | Serum or plasma | Serum | ||||||
| Sample volume | 25 µL (+150 µL dead volume) | 20 µL (+150 µL dead volume) | 10 µL | ||||||
| Assay duration | ~30 min | ~50 min | ~150 min | ||||||
| Assay unit | S/CO* | U/mL | ISR | ||||||
| Interpretation | |||||||||
| Nonreactive | <0.50 | <0.75 | <0.50 | <20 | <20 | <5 | ≤0.90 | ≤0.90 | ≤0.90 |
| Gray zone/equivocal† | 0.50 to <1.00 | 0.75 to <1.00 | 0.50 to <1.00 | 20 to <40 | No equivocal zone | 5 to <20 | 0.91 to <1.10 | 0.91 to <1.10 | 0.91 to <1.10 |
| Reactive | ≥1.00 | ≥1.00 | ≥1.00 | ≥40 | ≥20 | ≥20 | ≥1.10 | ≥1.10 | ≥1.10 |
| Antigen | VCA p18 | EBNA-1 p72 | Synthetic peptide p18 | EBNA-1 | Affinity-purified VCA antigen | Recombinant EBNA-1 | |||
| EA IgG availability | No | Yes | Yes | ||||||
*Sample RLU/cut-off RLU; †Gray zone for Architect and Equivocal for Liaison and Platelia.
Abbreviations: CLIA, chemiluminescence immunoassay; CMIA, Chemiluminescent microparticle immunoassay; EA, Epstein-Barr virus early antigen; EBNA, Epstein-Barr virus nuclear antigen; ELISA, enzyme-linked immunosorbent assay; ISR, immune status ratio; RLU, relative light unit; VCA, viral capsid antigen.